Navigation Links
ChemoCentryx Reports One-Year Results from PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Treating Patients with Crohn's Disease at the United European Gastroenterology Federation (UEGW) Meeting
Date:10/27/2010

MOUNTAIN VIEW, Calif., Oct. 27 /PRNewswire/ -- ChemoCentryx, Inc., today announced that it reported one-year results from the Company's PROTECT-1 Study (the Prospective Randomized Oral Therapy Evaluation in Crohn's disease Trial) of Traficet-EN™ (CCX282-B) in patients with moderate-to-severe Crohn's disease. Traficet-EN, an orally bioavailable CCR9-specific chemokine receptor antagonist showed clinical efficacy in a 12-week Induction period, as well as a 36-week Maintenance period. Specifically, Traficet-EN demonstrated evidence of clinical efficacy in the reduction of disease activity as defined by a 70-point or 100-point decrease in the Crohn's Disease Activity Index (CDAI) during the Induction period.  Furthermore, approximately 50% of patients receiving Traficet-EN in the Maintenance period were in clinical remission (CDAI less than 150) by the end of the 36 weeks compared to 31% of patients receiving placebo.  Traficet-EN continued to be safe and well tolerated.  Phase III clinical trials designed to evaluate Traficet-EN in patients with moderate-to-severe Crohn's disease are expected to initiate before the end of the year.  

Additionally, conclusive evidence was provided that the involvement of CCR9 and its chemokine ligand (TECK) in inflammatory bowel disease (IBD) is not just restricted to the small bowel, but is relevant to inflammation of the large bowel as well.  These findings as well as the Traficet-EN one-year study results were highlighted at the 18th United European Gastroenterology Federation (UEGW) meeting in Barcelona, Spain in a poster presentation entitled "One-Year Results from PROTECT-1 Study of Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease" and in an oral presentation entitled "CCR9 Inhibition in the Treatment of Colonic Inflammation" presented by Dr. Juan C. Jaen, Senior Vice President, Drug Discovery and Chief Scientific Officer, ChemoCentryx, Inc.


'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD)
2. ChemoCentryx Reports that Traficet-EN Maintains Remission in Crohns Disease at the Digestive Disease Week (DDW) 2010 Conference
3. ChemoCentryx Initiates Clinical Trial of CCX168, A Novel Small Molecule C5aR Antagonist for the Treatment of Inflammatory and Autoimmune Diseases
4. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
5. ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-ENs Effectiveness in Maintaining Remission in Patients with Crohns Disease
6. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
7. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
8. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
9. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
10. Mylan Reports Adjusted Diluted EPS of $0.43; Reaffirms 2010 Adjusted Diluted EPS Guidance of $1.55 - $1.65
11. Abaxis Reports Financial Performance with Record Sales for the Second Quarter of Fiscal 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)...  The American Diabetes Association is recommending a ... with diabetes and that all people with diabetes ... in keeping with recent changes to guidelines for ... of Cardiology (ACC) and American Heart Association (AHA). ... changes to the Association,s annual revised Standards of ...
(Date:12/24/2014)... N.C. , Dec. 23, 2014  Endo Pharmaceuticals ... ENDP ) (TSX: ENL), and BioDelivery Sciences International, ... they have submitted a New Drug Application (NDA) for ... Drug Administration (FDA).  Buprenorphine HCl Buccal Film is under ... require daily, around-the-clock, long-term opioid treatment and for which ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... 2011 Today, Children,s Hospital at Scott ... and the only stand-alone facility between Dallas and Austin, opened ... used Scott & White,s state-of-the-art Simulation Center for a mock ... housed in Scott & White Hospital-Temple, before moving patients to ...
... 4, 2011 /PRNewswire/ -- PLC Systems Inc. ... technologies, today announced that it had signed an agreement ... to distribute its innovative RenalGuard System™ in France and ... ACIST will be the exclusive distributor of PLC,s RenalGuard® ...
Cached Medicine Technology:Children's Hospital at Scott & White Opens 2Children's Hospital at Scott & White Opens 3Children's Hospital at Scott & White Opens 4PLC Systems Signs ACIST Medical Systems, to Distribute RenalGuard® in France and Germany 2PLC Systems Signs ACIST Medical Systems, to Distribute RenalGuard® in France and Germany 3PLC Systems Signs ACIST Medical Systems, to Distribute RenalGuard® in France and Germany 4
(Date:12/26/2014)... 2014 Parker & Sons, Inc. ... in heating, cooling and plumbing contractor services throughout ... services in 2014 with regard to air-conditioning systems. ... is known for its incredibly hot summers. Working ... intricacies and details of a wide variety of ...
(Date:12/25/2014)... 2014 The click strand ... strength and durability. Today, the business announces a ... valid until Jan. 30, 2015. , Click strand ... hardwood. BambooFlooringChina.com is a well-known brand in the ... to find a reliable bamboo flooring supplier. , ...
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying ... of discounted prom dresses, most of which are priced ... the company, the promotion is valid until Jan. 22, ... the UK market. , The prom dresses in this ... styles: A-line strapless, empire strapless chiffon, one shoulder, floor-length, ...
(Date:12/25/2014)... sells many bamboo products and the business is famous ... announces big discounts on its bamboo mats , which ... the world’s leader in bamboo flooring. According to the ... 2015. , The bamboo mats are made from well-treated ... the bamboo strips for the mats are boiled and ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... BETHESDA, Md., Aug. 19 /PRNewswire-Asia/ -- Chindex ... independent American provider of Western,healthcare products and services in ... entered into a contract to supply EUR5 million in,laboratory ... China,s,Qinghai Province. The purchase is being financed by the ...
... , ELM GROVE, Wis., Aug. 19 A webinar on JCAHO ... partment Core Measures: A c hieving Successful Quality Outcomes ... to aid Hospital Emergency Departments in instituting treatment standards as ... CAP patients. Compliance with JCAHO Core Measures produces better outcomes for ...
... warn of toxic buildup from paraffin, suggest beeswax instead ... candles, used mainly for romantic ambiance, fragrance and light, ... , The candles, which are made from petroleum, are ... researchers said in a study to be presented Wednesday ...
... , WASHINGTON, Aug. 19 The ... Tobacco-Free Kids: , , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ... and Drug Administration announcement today that it is establishing the Center ... highly respected and experienced public health leader, as the Center Director ...
... , , , ... and Prevention (CDC)(1) and LYSOL(R) brand products are proud to announce the launch ... www.oop k i ds.com , an interactive site ... was created in a continued effort to educate children and their parents about ...
... workers, new federal guidelines say , WEDNESDAY, Aug. 19 ... keeping employees six-feet apart are all ways to reduce ... America,s businesses, government experts said in new guidelines issued ... as the fall/winter flu season approaches, because the extent ...
Cached Medicine News:Health News:Chindex International, Inc. Announces New CDC Contract 2Health News:Chindex International, Inc. Announces New CDC Contract 3Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 2Health News:Compirion Hosts Free Webinar on Achieving JCAHO-Compliant Quality Outcomes 3Health News:Tobacco-Free Kids Welcomes Formation of FDA's Center for Tobacco Products and Selection of Center Director 2Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 2Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 3Health News:The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 4Health News:Businesses Need Swine Flu Action Plan: Experts 2Health News:Businesses Need Swine Flu Action Plan: Experts 3
For the quantitative in vitro determination of Digoxin in human serum....
For the quantitative in vitro determination of Microalbumin in urine....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Medicine Products: